
Stryker Corporation
- Jurisdiction
United States - LEI
5493002F0SC4JTBU5137 - ISIN
US8636671013 (SYK )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€284.91 11.5% overvalued - Financial strength (Piotroski F-Value)
-
6
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
4
/ 7
Quick analysis
Stryker Corporation – Leading Medical Device Company with a Broad Portfolio
Brief Summary for Investors: Stryker is an established US medical device company with a market capitalization of approximately $128 billion. The company serves two main segments: Orthopedics/Spine, MedSurg, and Neurotechnology, and markets its products to healthcare facilities worldwide.
Development The share price has shown a clear upward trend over the past five years, driven by consistent revenue and profit growth. Annual revenue increased from $14.4 billion (2020) to $20.5 billion (2023). However, the latest quarterly figures show some volatility, with a significant decline in revenue and EBITDA in the most recent reported quarter (Q1 2025) compared to the previous quarter (Q4 2024). Profitability ratios (ROE, ROA) are currently moderate, and the debt-to-equity ratio of 1.2 reflects reasonable but substantial leverage.
Opportunities:
- Demographic trend: The aging global population is driving long-term demand for elective procedures such as hip and knee replacements.
- Broad portfolio: Diversification across multiple medical specialties reduces dependence on a single market and offers cross-selling opportunities.
- Innovation: Stryker's focus on technological advances, particularly in robotics (surgical navigation systems) and minimally invasive procedures, secures competitive advantages.
Risks:
- Regulatory interventions: The healthcare sector is vulnerable to regulatory changes and pricing pressure from health insurers and governments.
- Economic Sensitivity: Elective surgeries can be postponed during economic downturns, which can negatively impact revenues in the short term.
- Operational Volatility: Recent quarterly results indicate potential operational irregularities or seasonal effects that warrant monitoring.
Additional Notes: In the last 60 days, sales were reported by a politician, several senior executives, and one director. Insider transaction volumes were substantial, which can be considered an indicator for close monitoring.
Conclusion: Stryker is a high-quality, profitable company in a structurally growing market. The long-term fundamentals are strong, but the latest quarterly results raise questions about short-term operating performance. The current quarter-on-quarter decline in revenue and profitability warrants increased attention. Investors should await the next quarterly reports to assess whether this represents a seasonal blip or the beginning of a trend break. The long-term investment case remains intact due to demographic drivers and market positioning.
Read full AI analysisCreated
Profile
Stryker Corporation operates as a medical technology company. Read full profile
Fundamentals
- Net revenue
€20.32B - Gross margin
63.8% - EBIT
€3.30B - EBIT margin
16.2% - Net income
€2.49B - Net margin
12.3%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
|
| |
|
|
Stock price
Dividends
- Last dividend amount
-
$0.84 - Ex date
-
- Payment date
-
- Dividend payout ratio
-
42.9%
Analyst ratings
No analyst ratings available
Insider Transactions
Name | Title | Transaction Date | Shares | Price | Value |
---|---|---|---|---|---|
Menon Viju | Group President |
|
|
|
|
Fletcher Robert S | VP, Chief Legal Officer |
|
|
|
|
STRYKER RONDA E | N/A |
|
|
|
|
Congress transactions
Name | Transaction date | Value |
---|---|---|
Thomas Kean | September 18, 2025 | $1.00K–$15.00K |
Thomas Kean | August 20, 2025 | $15.00K–$50.00K |
Thomas Kean | July 16, 2025 | $15.00K–$50.00K |
Jefferson Shreve | June 22, 2025 | $50.00K–$100.00K |
Julie Johnson | May 14, 2025 | $1.00K–$15.00K |
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Terry Smith |
|
|
|
Sell |
Ray Dalio |
|
|
|
Sell |